Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ELOS's Cash to Debt is ranked higher than
97% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. ELOS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ELOS' s Cash to Debt Range Over the Past 10 Years
Min: 65.7  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.76
ELOS's Equity to Asset is ranked higher than
71% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ELOS: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
ELOS' s Equity to Asset Range Over the Past 10 Years
Min: 0.61  Med: 0.76 Max: 0.89
Current: 0.76
0.61
0.89
Interest Coverage No Debt
ELOS's Interest Coverage is ranked higher than
96% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 71.73 vs. ELOS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ELOS' s Interest Coverage Range Over the Past 10 Years
Min: 126.63  Med: 272.84 Max: No Debt
Current: No Debt
F-Score: 7
Z-Score: 4.42
M-Score: -2.69
WACC vs ROIC
8.37%
1.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.71
ELOS's Operating margin (%) is ranked lower than
53% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. ELOS: 1.71 )
Ranked among companies with meaningful Operating margin (%) only.
ELOS' s Operating margin (%) Range Over the Past 10 Years
Min: -43.96  Med: -2.35 Max: 29.62
Current: 1.71
-43.96
29.62
Net-margin (%) 1.04
ELOS's Net-margin (%) is ranked lower than
52% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.25 vs. ELOS: 1.04 )
Ranked among companies with meaningful Net-margin (%) only.
ELOS' s Net-margin (%) Range Over the Past 10 Years
Min: -43.1  Med: -1.27 Max: 33.9
Current: 1.04
-43.1
33.9
ROE (%) 1.47
ELOS's ROE (%) is ranked higher than
50% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. ELOS: 1.47 )
Ranked among companies with meaningful ROE (%) only.
ELOS' s ROE (%) Range Over the Past 10 Years
Min: -19.9  Med: -1.43 Max: 23.36
Current: 1.47
-19.9
23.36
ROA (%) 1.09
ELOS's ROA (%) is ranked higher than
54% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.44 vs. ELOS: 1.09 )
Ranked among companies with meaningful ROA (%) only.
ELOS' s ROA (%) Range Over the Past 10 Years
Min: -14.56  Med: -1.06 Max: 20.05
Current: 1.09
-14.56
20.05
ROC (Joel Greenblatt) (%) 7.88
ELOS's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. ELOS: 7.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ELOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -397.3  Med: -14.99 Max: 212.39
Current: 7.88
-397.3
212.39
Revenue Growth (3Y)(%) 0.90
ELOS's Revenue Growth (3Y)(%) is ranked lower than
62% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ELOS: 0.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ELOS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.8 Max: 190.6
Current: 0.9
0
190.6
EBITDA Growth (3Y)(%) -17.70
ELOS's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ELOS: -17.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ELOS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.2  Med: 3.2 Max: 99.5
Current: -17.7
-46.2
99.5
EPS Growth (3Y)(%) 62.00
ELOS's EPS Growth (3Y)(%) is ranked higher than
87% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ELOS: 62.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ELOS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64  Med: -0.6 Max: 98.2
Current: 62
-64
98.2
GuruFocus has detected 4 Warning Signs with Syneron Medical Ltd $ELOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELOS's 10-Y Financials

Financials (Next Earnings Date: 2017-02-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ELOS Guru Trades in Q4 2015

Ronald Muhlenkamp 10,255 sh (New)
Charles Brandes 1,745,669 sh (+206.06%)
Chuck Royce 663,159 sh (+7.23%)
Mario Gabelli 24,000 sh (unchged)
Jim Simons 900,606 sh (-1.33%)
» More
Q1 2016

ELOS Guru Trades in Q1 2016

Charles Brandes 2,509,446 sh (+43.75%)
Chuck Royce 713,159 sh (+7.54%)
Jim Simons 928,806 sh (+3.13%)
Mario Gabelli 24,000 sh (unchged)
Ronald Muhlenkamp Sold Out
» More
Q2 2016

ELOS Guru Trades in Q2 2016

Chuck Royce 788,159 sh (+10.52%)
Charles Brandes 2,723,535 sh (+8.53%)
Jim Simons 965,106 sh (+3.91%)
Mario Gabelli 24,000 sh (unchged)
» More
Q3 2016

ELOS Guru Trades in Q3 2016

Charles Brandes 3,414,913 sh (+25.39%)
Jim Simons 1,021,606 sh (+5.85%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 420,659 sh (-46.63%)
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:NAS:AXGN, OTCPK:IPDQF, NAS:TCMD, NAS:XENT, NAS:CUTR, NAS:EXAC, NYSE:IVC, NYSE:GI, NAS:RTIX, NAS:ARAY, NAS:IRIX, NAS:OBLN, NAS:NVCN, NAS:VRAY, NAS:IRMD, NAS:ACRX, NAS:FONR, NAS:CGNT, OTCPK:MZRTF, NAS:EDAP » details
Traded in other countries:FGD.Germany,
Syneron Medical Ltd designs, develops & markets aesthetic medical products based on its proprietary technologies. Its offers Skin Rejuvenation, Age Spots, Cellulite Reduction, Acne, & Hair Removal among others.

Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company's proprietary ELOS technology, which combines optical and electrical energy, enhances the user's ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. Its patent portfolio (including patents held by subsidiaries) consisted of 140 issued U.S. patents.The Company's trademarks include Syneron, Elos, Candela, Ultrashape, Litetouch, VelaShape, VelaSmooth, Sublative, eTwo, eMax, ePRIME, eLase, elosPlus, Elure, Motif, Co2re, eMatrix, Matrix IR, Matrix RF, Refirme. It competes with large pharmaceutical companies that have entered the aesthetic device market, such as Valeant Pharmaceuticals International Inc. (which acquired Solta Medical Inc. in 2014), Merz Pharma Group (which acquired Ulthera, Inc. in 2014) and Actevis PLC (which acquired Allergan, Inc. in 2014). Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and hyaluronic acid injections, face lifts, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company's products are medical devices and cosmetics subject to extensive and rigorous regulation by the FDA, as well as other U.S. and foreign regulatory bodies.

Ratios

vs
industry
vs
history
P/E(ttm) 86.00
ELOS's P/E(ttm) is ranked lower than
87% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 26.07 vs. ELOS: 86.00 )
Ranked among companies with meaningful P/E(ttm) only.
ELOS' s P/E(ttm) Range Over the Past 10 Years
Min: 6.8  Med: 18.07 Max: 1035
Current: 86
6.8
1035
PE(NRI) 86.00
ELOS's PE(NRI) is ranked lower than
88% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 25.71 vs. ELOS: 86.00 )
Ranked among companies with meaningful PE(NRI) only.
ELOS' s PE(NRI) Range Over the Past 10 Years
Min: 6.8  Med: 18.07 Max: 1242
Current: 86
6.8
1242
Price/Owner Earnings (ttm) 30.82
ELOS's Price/Owner Earnings (ttm) is ranked higher than
50% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 31.72 vs. ELOS: 30.82 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ELOS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.13  Med: 27.78 Max: 984.55
Current: 30.82
6.13
984.55
P/B 1.43
ELOS's P/B is ranked higher than
79% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. ELOS: 1.43 )
Ranked among companies with meaningful P/B only.
ELOS' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 1.58 Max: 5.36
Current: 1.43
0.58
5.36
P/S 1.03
ELOS's P/S is ranked higher than
78% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. ELOS: 1.03 )
Ranked among companies with meaningful P/S only.
ELOS' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.71 Max: 9.26
Current: 1.03
0.77
9.26
PFCF 23.13
ELOS's PFCF is ranked higher than
59% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. ELOS: 23.13 )
Ranked among companies with meaningful PFCF only.
ELOS' s PFCF Range Over the Past 10 Years
Min: 4.33  Med: 19.02 Max: 285.19
Current: 23.13
4.33
285.19
POCF 17.06
ELOS's POCF is ranked higher than
56% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.89 vs. ELOS: 17.06 )
Ranked among companies with meaningful POCF only.
ELOS' s POCF Range Over the Past 10 Years
Min: 4.16  Med: 17.7 Max: 773.57
Current: 17.06
4.16
773.57
EV-to-EBIT 43.27
ELOS's EV-to-EBIT is ranked lower than
79% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. ELOS: 43.27 )
Ranked among companies with meaningful EV-to-EBIT only.
ELOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -119.6  Med: -3.8 Max: 691.6
Current: 43.27
-119.6
691.6
EV-to-EBITDA 16.41
ELOS's EV-to-EBITDA is ranked lower than
52% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 16.63 vs. ELOS: 16.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -294.8  Med: 12.7 Max: 172.2
Current: 16.41
-294.8
172.2
Current Ratio 2.94
ELOS's Current Ratio is ranked higher than
58% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. ELOS: 2.94 )
Ranked among companies with meaningful Current Ratio only.
ELOS' s Current Ratio Range Over the Past 10 Years
Min: 2.59  Med: 3.82 Max: 10.72
Current: 2.94
2.59
10.72
Quick Ratio 2.19
ELOS's Quick Ratio is ranked higher than
55% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ELOS: 2.19 )
Ranked among companies with meaningful Quick Ratio only.
ELOS' s Quick Ratio Range Over the Past 10 Years
Min: 1.9  Med: 3.51 Max: 10.39
Current: 2.19
1.9
10.39
Days Inventory 129.23
ELOS's Days Inventory is ranked higher than
51% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 131.45 vs. ELOS: 129.23 )
Ranked among companies with meaningful Days Inventory only.
ELOS' s Days Inventory Range Over the Past 10 Years
Min: 57.94  Med: 108.11 Max: 205.18
Current: 129.23
57.94
205.18
Days Sales Outstanding 65.35
ELOS's Days Sales Outstanding is ranked higher than
53% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 67.65 vs. ELOS: 65.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.35  Med: 80.76 Max: 120.06
Current: 65.35
65.35
120.06
Days Payable 39.27
ELOS's Days Payable is ranked lower than
68% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 56.36 vs. ELOS: 39.27 )
Ranked among companies with meaningful Days Payable only.
ELOS' s Days Payable Range Over the Past 10 Years
Min: 39.27  Med: 67.37 Max: 131.41
Current: 39.27
39.27
131.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.30
ELOS's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ELOS: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -70.6  Med: -7.7 Max: 0.3
Current: 0.3
-70.6
0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 172.00
ELOS's Price/Net Cash is ranked lower than
94% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. ELOS: 172.00 )
Ranked among companies with meaningful Price/Net Cash only.
ELOS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.06  Med: 6.78 Max: 177
Current: 172
1.06
177
Price/Net Current Asset Value 2.63
ELOS's Price/Net Current Asset Value is ranked higher than
83% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. ELOS: 2.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ELOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.86  Med: 2.79 Max: 7.94
Current: 2.63
0.86
7.94
Price/Tangible Book 1.65
ELOS's Price/Tangible Book is ranked higher than
84% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ELOS: 1.65 )
Ranked among companies with meaningful Price/Tangible Book only.
ELOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.71  Med: 2.03 Max: 7.72
Current: 1.65
0.71
7.72
Price/Projected FCF 6.67
ELOS's Price/Projected FCF is ranked lower than
82% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. ELOS: 6.67 )
Ranked among companies with meaningful Price/Projected FCF only.
ELOS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.46  Med: 1.46 Max: 43.93
Current: 6.67
0.46
43.93
Price/Median PS Value 0.61
ELOS's Price/Median PS Value is ranked higher than
82% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ELOS: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
ELOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.18 Max: 7.84
Current: 0.61
0.5
7.84
Price/Graham Number 2.51
ELOS's Price/Graham Number is ranked lower than
54% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. ELOS: 2.51 )
Ranked among companies with meaningful Price/Graham Number only.
ELOS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.93  Med: 2.01 Max: 10.02
Current: 2.51
0.93
10.02
Earnings Yield (Greenblatt) (%) 2.29
ELOS's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. ELOS: 2.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ELOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 7.4 Max: 6887.2
Current: 2.29
0.1
6887.2

More Statistics

Revenue (TTM) (Mil) $294.1
EPS (TTM) $ 0.10
Beta0.88
Short Percentage of Float0.60%
52-Week Range $6.11 - 9.10
Shares Outstanding (Mil)35.27

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 291 304
EPS ($) 0.27 0.43
EPS w/o NRI ($) 0.27 0.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ELOS

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 16 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 12 2009 
Seth Klarman Buys First American Corp., Universal Compression Holdings, School Specialty Inc., Sells Aug 13 2007 
Seth Klarman Buys Home Depot Inc., InfoSpace Inc., Multimedia Games Inc., Sells Laidlaw Internationa Nov 13 2006 

More From Other Websites
ETFs with exposure to Syneron Medical Ltd. : December 9, 2016 Dec 09 2016
Top Ranked Momentum Stocks to Buy for December 9th Dec 09 2016
Hedge Funds Aren’t Crazy About Syneron Medical Ltd. (ELOS) Anymore Dec 09 2016
5 Reasonable Breakout Stocks for Exceptional Returns Dec 08 2016
ETFs with exposure to Syneron Medical Ltd. : November 28, 2016 Nov 28 2016
Syneron Medical Ltd. :ELOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 Nov 23 2016
Syneron Medical to Participate in the Canaccord Genuity Medical Technologies and Diagnostics Forum Nov 11 2016
Edited Transcript of ELOS earnings conference call or presentation 9-Nov-16 1:30pm GMT Nov 09 2016
Syneron Medical Reports Third Quarter 2016 Revenue of $71.5 Million Nov 09 2016
Q3 2016 Syneron Medical Ltd Earnings Release - Before Market Open Nov 09 2016
Syneron Medical Reports Third Quarter 2016 Revenue of $71.5 Million Nov 09 2016
Syneron Candela Announces FDA Clearance Of Profound™ SubQ To Improve The Appearance Of Cellulite,... Nov 08 2016
Syneron Candela Announces FDA Clearance Of Profound™ SubQ To Improve The Appearance Of Cellulite,... Nov 08 2016
Your Personal Healthcare Investment Plan Oct 27 2016
Daily Wrap: The Biggest Hedge Fund Moves of the Day Oct 19 2016
Here’s Why Zynerba Pharmaceuticals, Kratos Defense, Rogers Communications, and Two Other Stocks... Oct 17 2016
Syneron Medical Strengthens Senior Management and Announces Preliminary Third Quarter 2016 Revenue Oct 17 2016
Syneron Medical Strengthens Senior Management and Announces Preliminary Third Quarter 2016 Revenue Oct 17 2016
ETF’s with exposure to Syneron Medical Ltd. : October 6, 2016 Oct 06 2016
ETF’s with exposure to Syneron Medical Ltd. : September 22, 2016 Sep 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)